DESFERRIOXAMINE TREATMENT REDUCES BLOOD TRANSFUSION REQUIREMENTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
- 1 January 1992
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 80 (1) , 121-124
- https://doi.org/10.1111/j.1365-2141.1992.tb06411.x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietinBritish Journal of Haematology, 1991
- Desferrioxamine versus erythropoietin for treatment of dialysis anaemiaThe Lancet, 1990
- The use of chelating agents in the treatment of aluminum overloadJournal of Toxicology: Clinical Toxicology, 1989
- DESFERRIOXAMINE, ANAEMIA, AND HAEMODIALYSISThe Lancet, 1988
- IMPROVEMENT IN THE ERYTHROPOIESIS OF CHRONIC HAEMODIALYSIS PATIENTS WITH DESFERRIOXAMINEThe Lancet, 1988
- Treatment of Hemodialysis-Related Porphyria Cutanea Tarda with DeferoxamineNew England Journal of Medicine, 1987
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982
- IMPROVEMENT IN IRON STATUS AND LIVER FUNCTION IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD WITH LONG-TERM SUBCUTANEOUS DESFERRIOXAMINEThe Lancet, 1979
- Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical ProgressBMJ, 1974
- Changes in blood and plasma volumes during growthThe Journal of Pediatrics, 1971